Wildcat Capital Management LLC held its stake in Editas Medicine, Inc. (NASDAQ:EDIT) during the 2nd quarter, according to its most recent 13F filing with the SEC. The fund owned 41,324 shares of the company’s stock at the close of the 2nd quarter. Editas Medicine accounts for approximately 0.2% of Wildcat Capital Management LLC’s holdings, making the stock its 16th largest holding. Wildcat Capital Management LLC owned about 0.10% of Editas Medicine worth $693,000 as of its most recent SEC filing.

A number of other hedge funds have also made changes to their positions in EDIT. Vanguard Group Inc. increased its stake in Editas Medicine by 47.0% during the 1st quarter. Vanguard Group Inc. now owns 1,935,173 shares of the company’s stock valued at $43,193,000 after purchasing an additional 618,789 shares in the last quarter. FMR LLC grew its stake in shares of Editas Medicine by 7.3% in the 1st quarter. FMR LLC now owns 5,901,489 shares of the company’s stock worth $131,721,000 after acquiring an additional 403,099 shares in the last quarter. Clough Capital Partners L P grew its stake in shares of Editas Medicine by 678.0% in the 1st quarter. Clough Capital Partners L P now owns 392,087 shares of the company’s stock worth $8,751,000 after acquiring an additional 341,687 shares in the last quarter. ARK Investment Management LLC grew its stake in shares of Editas Medicine by 121.9% in the 2nd quarter. ARK Investment Management LLC now owns 510,187 shares of the company’s stock worth $8,561,000 after acquiring an additional 280,265 shares in the last quarter. Finally, Northern Trust Corp grew its stake in shares of Editas Medicine by 245.9% in the 2nd quarter. Northern Trust Corp now owns 373,149 shares of the company’s stock worth $6,261,000 after acquiring an additional 265,273 shares in the last quarter. Institutional investors and hedge funds own 69.37% of the company’s stock.

EDIT has been the subject of several recent analyst reports. Zacks Investment Research upgraded shares of Editas Medicine from a “hold” rating to a “buy” rating and set a $19.00 target price for the company in a research note on Wednesday, July 12th. SunTrust Banks, Inc. initiated coverage on shares of Editas Medicine in a research note on Thursday, July 13th. They issued a “hold” rating and a $17.00 target price for the company. Cann initiated coverage on shares of Editas Medicine in a research note on Monday, July 17th. They issued a “market perform” rating for the company. Oppenheimer Holdings, Inc. reiterated a “market perform” rating on shares of Editas Medicine in a research note on Tuesday, July 18th. Finally, J P Morgan Chase & Co set a $27.00 target price on shares of Editas Medicine and gave the stock a “hold” rating in a research note on Wednesday, August 9th. Six research analysts have rated the stock with a hold rating, four have given a buy rating and one has assigned a strong buy rating to the company. The stock presently has a consensus rating of “Buy” and an average target price of $25.52.

Editas Medicine, Inc. (NASDAQ:EDIT) traded up 1.23% during mid-day trading on Thursday, hitting $23.79. 568,302 shares of the stock traded hands. Editas Medicine, Inc. has a 52-week low of $12.43 and a 52-week high of $28.50. The firm’s 50-day moving average is $22.06 and its 200 day moving average is $22.06. The firm’s market cap is $973.63 million.

Editas Medicine (NASDAQ:EDIT) last posted its quarterly earnings results on Wednesday, August 9th. The company reported ($0.65) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.64) by ($0.01). The company had revenue of $3.10 million during the quarter, compared to analysts’ expectations of $2.20 million. Editas Medicine had a negative return on equity of 67.75% and a negative net margin of 2,091.36%. Editas Medicine’s revenue for the quarter was down 8.8% compared to the same quarter last year. During the same period in the prior year, the firm earned ($0.54) EPS. Equities analysts predict that Editas Medicine, Inc. will post ($2.88) EPS for the current fiscal year.

TRADEMARK VIOLATION NOTICE: “Wildcat Capital Management LLC Has $693,000 Stake in Editas Medicine, Inc. (EDIT)” was first reported by Watch List News and is the sole property of of Watch List News. If you are reading this report on another website, it was copied illegally and reposted in violation of US & international trademark & copyright laws. The correct version of this report can be read at https://www.watchlistnews.com/wildcat-capital-management-llc-has-693000-stake-in-editas-medicine-inc-edit/1610554.html.

In other news, insider Katrine Bosley sold 8,333 shares of Editas Medicine stock in a transaction dated Monday, October 2nd. The stock was sold at an average price of $24.78, for a total value of $206,491.74. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. In the last ninety days, insiders sold 51,665 shares of company stock valued at $1,083,165. 19.40% of the stock is owned by insiders.

Editas Medicine Profile

Editas Medicine, Inc is a genome editing company. It is engaged in treating patients with genetically defined diseases by correcting their disease-causing genes. It operates through developing and commercializing genome editing technology segment. It is developing a genome editing platform based on clustered, regularly interspaced short palindromic repeats (CRISPR) technology.

Institutional Ownership by Quarter for Editas Medicine (NASDAQ:EDIT)

Receive News & Ratings for Editas Medicine Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Editas Medicine Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.